2023 年 9 月 22 日 SPEAC 网络研讨会报告：感音神经性听力损失、拉萨病毒病和疫苗。

IF 4.5 3区医学 Q2 IMMUNOLOGY

Vaccine Pub Date : 2024-11-22 DOI:10.1016/j.vaccine.2024.126525

Nicholas S. Reed , Carmen C. Brewer , Gideon Akintunde , Faustina F. Blackie , Lovelyn Charles , Patricia Fast , Paul-Henri Lambert , Sylvanus Okogbenin , Slobodan Paessler , Daniel D. Pinschewer , Karina A. Top , Steven B. Black , Cornelia L. Dekker

{"title":"2023 年 9 月 22 日 SPEAC 网络研讨会报告：感音神经性听力损失、拉萨病毒病和疫苗。","authors":"Nicholas S. Reed , Carmen C. Brewer , Gideon Akintunde , Faustina F. Blackie , Lovelyn Charles , Patricia Fast , Paul-Henri Lambert , Sylvanus Okogbenin , Slobodan Paessler , Daniel D. Pinschewer , Karina A. Top , Steven B. Black , Cornelia L. Dekker","doi":"10.1016/j.vaccine.2024.126525","DOIUrl":null,"url":null,"abstract":"<div><div>Lassa virus (LASV) belongs to the Arenavirus family. LASV is endemic in several West Africa countries and causes viral hemorrhagic fevers. The Nigeria CDC has reported that an outbreak in 2024 in 28 states has resulted in 7767 suspected cases of Lassa fever, 971 confirmed cases and 166 confirmed deaths up to 11 August. Since infection with LASV can result in sensorineural hearing loss (SNHL) in up to 30% of patients, there are questions about whether triggering the immune response by immunization with LASV vaccines could potentially cause SNHL, although this has not been shown in clinical trials to date. To address this issue, the Coalition for Epidemic Preparedness Innovations (CEPI) and the Brighton Collaboration (BC) Safety Platform for Emergency vACcines (SPEAC) convened a three-hour webinar on 22 September 2023 to review what is known from both animal studies and human clinical trials and how hearing assessments in future clinical trials can help to assess the risk. This report summarizes the evidence presented and provides considerations for hearing assessment in expanded human trials of LASV vaccine candidates in children and adults.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"43 ","pages":"Article 126525"},"PeriodicalIF":4.5000,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Report of a SPEAC webinar 22 september 2023: Sensorineural hearing loss, lassa virus disease and vaccines\",\"authors\":\"Nicholas S. Reed , Carmen C. Brewer , Gideon Akintunde , Faustina F. Blackie , Lovelyn Charles , Patricia Fast , Paul-Henri Lambert , Sylvanus Okogbenin , Slobodan Paessler , Daniel D. Pinschewer , Karina A. Top , Steven B. Black , Cornelia L. Dekker\",\"doi\":\"10.1016/j.vaccine.2024.126525\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Lassa virus (LASV) belongs to the Arenavirus family. LASV is endemic in several West Africa countries and causes viral hemorrhagic fevers. The Nigeria CDC has reported that an outbreak in 2024 in 28 states has resulted in 7767 suspected cases of Lassa fever, 971 confirmed cases and 166 confirmed deaths up to 11 August. Since infection with LASV can result in sensorineural hearing loss (SNHL) in up to 30% of patients, there are questions about whether triggering the immune response by immunization with LASV vaccines could potentially cause SNHL, although this has not been shown in clinical trials to date. To address this issue, the Coalition for Epidemic Preparedness Innovations (CEPI) and the Brighton Collaboration (BC) Safety Platform for Emergency vACcines (SPEAC) convened a three-hour webinar on 22 September 2023 to review what is known from both animal studies and human clinical trials and how hearing assessments in future clinical trials can help to assess the risk. This report summarizes the evidence presented and provides considerations for hearing assessment in expanded human trials of LASV vaccine candidates in children and adults.</div></div>\",\"PeriodicalId\":23491,\"journal\":{\"name\":\"Vaccine\",\"volume\":\"43 \",\"pages\":\"Article 126525\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2024-11-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vaccine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0264410X24012076\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X24012076","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

拉沙病毒（LASV）属于阿伦病毒科。拉沙病毒在西非多个国家流行，会引起病毒性出血热。尼日利亚疾病预防控制中心报告称，2024 年在 28 个州爆发的拉沙热疫情截至 8 月 11 日已导致 7767 例疑似病例、971 例确诊病例和 166 例确诊死亡病例。由于感染拉沙热病毒可导致多达 30% 的患者出现感音神经性听力损失 (SNHL)，因此有人质疑通过接种拉沙热疫苗来触发免疫反应是否可能导致感音神经性听力损失，尽管迄今为止临床试验尚未证明这一点。为解决这一问题，流行病防备创新联盟 (CEPI) 和布莱顿合作组织 (BC) 紧急疫苗安全平台 (SPEAC) 于 2023 年 9 月 22 日召开了一次三小时的网络研讨会，回顾了动物研究和人体临床试验的已知情况，以及未来临床试验中的听力评估如何帮助评估风险。本报告总结了所提供的证据，并为儿童和成人 LASV 候选疫苗扩大人体试验中的听力评估提供了考虑因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Report of a SPEAC webinar 22 september 2023: Sensorineural hearing loss, lassa virus disease and vaccines

Lassa virus (LASV) belongs to the Arenavirus family. LASV is endemic in several West Africa countries and causes viral hemorrhagic fevers. The Nigeria CDC has reported that an outbreak in 2024 in 28 states has resulted in 7767 suspected cases of Lassa fever, 971 confirmed cases and 166 confirmed deaths up to 11 August. Since infection with LASV can result in sensorineural hearing loss (SNHL) in up to 30% of patients, there are questions about whether triggering the immune response by immunization with LASV vaccines could potentially cause SNHL, although this has not been shown in clinical trials to date. To address this issue, the Coalition for Epidemic Preparedness Innovations (CEPI) and the Brighton Collaboration (BC) Safety Platform for Emergency vACcines (SPEAC) convened a three-hour webinar on 22 September 2023 to review what is known from both animal studies and human clinical trials and how hearing assessments in future clinical trials can help to assess the risk. This report summarizes the evidence presented and provides considerations for hearing assessment in expanded human trials of LASV vaccine candidates in children and adults.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Vaccine 医学-免疫学

CiteScore

8.70

自引率

5.50%

发文量

992

审稿时长

131 days

期刊介绍： Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.